ZIAC (bisoprolol fumarate and hydrochlorothiazide) by Teva is clinical pharmacology bisoprolol fumarate and hctz have been used individually and in combination for the treatment of hypertension. Approved for the management of hypertension. First approved in 1993.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
ZIAC is a fixed-dose combination of bisoprolol fumarate (a cardioselective beta-1 blocker) and hydrochlorothiazide (a thiazide diuretic) indicated for the management of hypertension. The two agents work synergistically—HCTZ 6.25 mg significantly enhances bisoprolol's antihypertensive effect while minimizing hypokalemia risk compared to higher HCTZ doses. This combination allows effective blood pressure control with lower individual doses and improved electrolyte tolerability.
Product is in late commercial lifecycle with minimal Part D activity (142 claims, 2023); team focus is likely on managed decline and defending market share against generic erosion.
CLINICAL PHARMACOLOGY Bisoprolol fumarate and HCTZ have been used individually and in combination for the treatment of hypertension. The antihypertensive effects of these agents are additive; HCTZ 6.25 mg significantly increases the antihypertensive effect of bisoprolol fumarate. The incidence of…
Worked on ZIAC at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Thiazide Diuretic
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ZIAC offers limited career growth due to its mature, declining lifecycle and minimal market share (142 Part D claims in 2023). Roles focus on managed decline, defending against generics, and cost-containment rather than innovation or launch acceleration—suitable for experienced professionals seeking stability but not career advancement.